COMMON MAPS
Map version new-york activity top-down
Main site Contact
Menu
↑ parent activity group ·
research dossier

S A S FOUNDATION FOR CANCER RESEARCH INC
BIBLE SCHOOL PARK, NY · EIN 352318752 · Form 990PF · FY2024 · NTEE T30 · Philanthropy & Grantmaking · Micro (<$100K)
revenue
$83K
expenses
$96K
net assets
$1.3M
employees
—
profile · synthesized from sources

S A S FOUNDATION FOR CANCER RESEARCH INC is a private foundation based in New York that funds cancer research initiatives. It supports scientific studies on drug resistance mechanisms, precision medicine, and immunotherapy approaches for various cancers, primarily through grants to research institutions like Roswell Park Alliance Foundation and Children's Hospital of Philadelphia.

named programs · 4 · from sources

What they call their work

Intermittent Fasting and Health Outcomes Study
Supports research comparing intermittent fasting with continuous caloric reduction in Black adults of faith.
Pancreatic Cancer Research Initiative
Funds research on HNF1A's role in tumor growth and microenvironment dynamics in pancreatic ductal adenocarcinoma, and supports organoid-based personalized medicine approaches.
Pediatric Solid Tumor Immunotherapy Research
Grants for epigenetic and immunotherapy approaches targeting relapsed or refractory pediatric solid tumors and neuroblastoma.
Triple-Negative Breast Cancer Research Grant
Supports proteome-wide overexpression perturbation studies to decipher doxorubicin resistance mechanisms in triple-negative breast cancer.
activities · 2 groups

What they do

  • Cancer Research Funding 4 activities
    • Funding epigenetic and immunotherapy research for pediatric solid tumors
      Funds research on epigenetic and immunotherapy approaches for relapsed or refractory pediatric solid tumors.
    • Funding personalized medicine research using organoids for pancreatic adenocarcinoma
      Funds personalized medicine research using organoids for pancreatic adenocarcinoma signature stratification.
    • Funding precision medicine approaches for neuroblastoma
      Funds precision medicine approaches to target Bcl2 survival proteins for highly lethal neuroblastoma.
    • Funding research on HNF1A's role in pancreatic ductal adenocarcinoma
      Funds research exploring the role of HNF1A in tumor growth and microenvironment dynamics in pancreatic ductal adenocarcinoma.
  • Uncategorized 2 activities
    • Funding research on drug resistance mechanisms in triple-negative breast cancer
      Funds research to decipher the drug resistance mechanism of triple-negative breast cancer against doxorubicin using proteome-wide overexpression perturbation.
    • Funding study comparing intermittent fasting and continuous caloric reduction in Black adults of faith
      Funds a study comparing intermittent fasting with continuous caloric reduction in Black adults of faith.
financials · form 990PF · fy2024
revenue
Total revenue$83K
Contributions & grants——
Program service revenue——
Investment income$37K44%
Other revenue$46K
expenses
Total expenses$96K
Program expenses—
Admin / overhead—
Fundraising—
Salaries & benefits—
Grants paid out$28K
balance sheet
Total assets$1.28M
Cash—
Investments—
Liabilities—
Net assets$1.28M
4 years on record · 2020–2024 · YoY revenue -12.9%
relationships · 3

Who they work with

  • CHILDREN'S HOSPITAL OF PHILADELPHIA Partner — Grant recipient for research on precision medicine targeting Bcl2 survival proteins in neuroblastoma.
  • LUSTGARTEN FOUNDATION Partner — Grant recipient for personalized medicine research involving organoids and pancreatic adenocarcinoma stratification.
  • ROSWELL PARK ALLIANCE FOUNDATION Partner — Recurrent grant recipient supporting cancer research in areas including triple-negative breast cancer, pancreatic cancer, and pediatric solid tumors.